Marian Urban1, Antonij Slavcev2, Tomas Gazdic3, Peter Ivak4, Josef Besik4, Ivan Netuka4. 1. Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic maub@ikem.cz. 2. Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 3. Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 4. Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Abstract
OBJECTIVES: Antibodies targeting angiotensin II type 1 receptor (AT1R) have been associated with malignant hypertension, autoimmune diseases and acute rejection and graft loss in solid organ transplantation. The aim of our study was to assess the impact of anti-AT1R antibodies on survival and incidence of acute cellular rejection (ACR) and pathology antibody-mediated rejection (pAMR) in a population of heart transplant recipients who were bridged to transplantation with a durable mechanical assist device Heart Mate II. METHODS: Sera of 69 consecutive heart transplant recipients transplanted between October 2008 and August 2014 were tested for the presence of angiotensin II type 1 receptor antibodies before Heart Mate II device implantation and at the time of transplantation. Overall survival and post-transplant rejection-free survival were compared between antibody-negative and antibody-positive recipients using Kaplan-Meier and log-rank tests. RESULTS: Anti-AT1R antibodies were present in 8 patients (11.6%) before Heart Mate II implantation. During the left ventricular assist device (LVAD) bridging, 44 patients (63.8%) who were initially anti-AT1R antibody-negative became positive, leaving 17 (24.6%) anti-AT1R antibody-negative patients at the time of transplantation for all comparisons. One- and 5-year survival was 88 ± 8 and 76 ± 10% for anti-AT1R antibody-negative and 87 ± 5 and 81 ± 7% for anti-AT1R antibody-positive patients, respectively (P = 0.582). Freedom from ACR at 1 year was 68 ± 12% for anti-AT1R-negative and 75 ± 6% for anti-AT1R-positive recipients (P = 0.218). None of the anti-AT1R-negative patients developed AMR 1 year post-transplantation, whereas freedom from pAMR in anti-AT1R-positive recipients was 98 ± 2% (P = 0.198). CONCLUSIONS: Our data showed no difference in the overall post-heart transplant survival and freedom from acute cellular and antibody-mediated rejection between anti-AT1R-negative and anti-AT1R-positive recipients. Further research is needed to assess the role of anti-AT1R antibodies in the risk stratification of LVAD-bridged recipients on the post-heart transplantation outcomes.
OBJECTIVES: Antibodies targeting angiotensin II type 1 receptor (AT1R) have been associated with malignant hypertension, autoimmune diseases and acute rejection and graft loss in solid organ transplantation. The aim of our study was to assess the impact of anti-AT1R antibodies on survival and incidence of acute cellular rejection (ACR) and pathology antibody-mediated rejection (pAMR) in a population of heart transplant recipients who were bridged to transplantation with a durable mechanical assist device Heart Mate II. METHODS: Sera of 69 consecutive heart transplant recipients transplanted between October 2008 and August 2014 were tested for the presence of angiotensin II type 1 receptor antibodies before Heart Mate II device implantation and at the time of transplantation. Overall survival and post-transplant rejection-free survival were compared between antibody-negative and antibody-positive recipients using Kaplan-Meier and log-rank tests. RESULTS: Anti-AT1R antibodies were present in 8 patients (11.6%) before Heart Mate II implantation. During the left ventricular assist device (LVAD) bridging, 44 patients (63.8%) who were initially anti-AT1R antibody-negative became positive, leaving 17 (24.6%) anti-AT1R antibody-negative patients at the time of transplantation for all comparisons. One- and 5-year survival was 88 ± 8 and 76 ± 10% for anti-AT1R antibody-negative and 87 ± 5 and 81 ± 7% for anti-AT1R antibody-positive patients, respectively (P = 0.582). Freedom from ACR at 1 year was 68 ± 12% for anti-AT1R-negative and 75 ± 6% for anti-AT1R-positive recipients (P = 0.218). None of the anti-AT1R-negative patients developed AMR 1 year post-transplantation, whereas freedom from pAMR in anti-AT1R-positive recipients was 98 ± 2% (P = 0.198). CONCLUSIONS: Our data showed no difference in the overall post-heart transplant survival and freedom from acute cellular and antibody-mediated rejection between anti-AT1R-negative and anti-AT1R-positive recipients. Further research is needed to assess the role of anti-AT1R antibodies in the risk stratification of LVAD-bridged recipients on the post-heart transplantation outcomes.
Authors: Nancy L Reinsmoen; Chih-Hung Lai; Harald Heidecke; Mark Haas; Kai Cao; Geraldine Ong; Mehrnoush Naim; Qi Wang; James Mirocha; Joseph Kahwaji; Ashley A Vo; Stanley C Jordan; Duska Dragun Journal: Transplantation Date: 2010-12-27 Impact factor: 4.939
Authors: Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham Journal: J Heart Lung Transplant Date: 2005-06-20 Impact factor: 10.247
Authors: G Wallukat; V Homuth; T Fischer; C Lindschau; B Horstkamp; A Jüpner; E Baur; E Nissen; K Vetter; D Neichel; J W Dudenhausen; H Haller; F C Luft Journal: J Clin Invest Date: 1999-04 Impact factor: 14.808
Authors: Gabriela Riemekasten; Aurélie Philippe; Melanie Näther; Torsten Slowinski; Dominik N Müller; Harald Heidecke; Marco Matucci-Cerinic; László Czirják; Ivo Lukitsch; Mike Becker; Angela Kill; Jacob M van Laar; Rusan Catar; Friedrich C Luft; Gerd R Burmester; Björn Hegner; Duska Dragun Journal: Ann Rheum Dis Date: 2010-11-15 Impact factor: 19.103
Authors: M Giral; Y Foucher; A Dufay; J P Duong Van Huyen; K Renaudin; A Moreau; A Philippe; B Hegner; R Dechend; H Heidecke; S Brouard; A Cesbron; S Castagnet; A Devys; J P Soulillou; D Dragun Journal: Am J Transplant Date: 2013-08-06 Impact factor: 8.086
Authors: M Taniguchi; L M Rebellato; J Cai; J Hopfield; K P Briley; C E Haisch; P G Catrou; P Bolin; K Parker; W T Kendrick; S A Kendrick; R C Harland; P I Terasaki Journal: Am J Transplant Date: 2013-08-13 Impact factor: 8.086
Authors: Sarah B See; Kevin J Clerkin; Peter J Kennel; Feifan Zhang; Matthew P Weber; Kortney J Rogers; Debanjana Chatterjee; Elena R Vasilescu; George Vlad; Yoshifumi Naka; Susan W Restaino; Maryjane A Farr; Veli K Topkara; Paolo C Colombo; Donna M Mancini; P Christian Schulze; Bruce Levin; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2017-03-24 Impact factor: 10.247
Authors: Sarah B See; Benjamin S Mantell; Kevin J Clerkin; Bryan Ray; E Rodica Vasilescu; Charles C Marboe; Yoshifumi Naka; Susan Restaino; Paolo C Colombo; Linda J Addonizio; Maryjane A Farr; Emmanuel Zorn Journal: Am J Transplant Date: 2020-04-26 Impact factor: 8.086
Authors: Morcos Atef Awad; Lawrence S C Czer; Dominic Emerson; Stanley Jordan; Michele A De Robertis; James Mirocha; Evan Kransdorf; David H Chang; Jignesh Patel; Michelle Kittleson; Danny Ramzy; Joshua S Chung; J Louis Cohen; Fardad Esmailian; Alfredo Trento; Jon A Kobashigawa Journal: J Am Heart Assoc Date: 2019-02-19 Impact factor: 5.501